APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genital Herpes Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Genital Herpes Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchGenital Herpes Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Genital Herpes Vaccine Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Genital Herpes Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genital Herpes Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Genital Herpes Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Genital Herpes Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Genital Herpes Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genital Herpes Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genital Herpes Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Genital Herpes Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Genital Herpes Vaccine market include GSK, Changsheng Biotechnology, Merck, Beike Bio and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Genital Herpes Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genital Herpes Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genital Herpes Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Genital Herpes Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Genital Herpes Vaccine Segment by Company

GSK

Changsheng Biotechnology

Merck

Beike Bio

BioNTech

Genital Herpes Vaccine Segment by Type

Zoster Vaccine Live

Recombinant Zoster Vaccine

Genital Herpes Vaccine Segment by Application

Male

Female

Genital Herpes Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Genital Herpes Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Genital Herpes Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Genital Herpes Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Genital Herpes Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genital Herpes Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genital Herpes Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genital Herpes Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Genital Herpes Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Genital Herpes Vaccine industry.

Chapter 3: Detailed analysis of Genital Herpes Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Genital Herpes Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Genital Herpes Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Genital Herpes Vaccine Industry Trends Table 2. Genital Herpes Vaccine Industry Drivers Table 3. Genital Herpes Vaccine Industry Opportunities and Challenges Table 4. Genital Herpes Vaccine Industry Restraints Table 5. Global Genital Herpes Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Genital Herpes Vaccine Revenue Share by Company (2021-2026) Table 7. Global Genital Herpes Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Genital Herpes Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Genital Herpes Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Genital Herpes Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Genital Herpes Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Genital Herpes Vaccine Company, Product Type & Application Table 13. Global Genital Herpes Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Genital Herpes Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Zoster Vaccine Live Table 18. Significant Companies of Recombinant Zoster Vaccine Table 19. Global Genital Herpes Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Genital Herpes Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Genital Herpes Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Genital Herpes Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Genital Herpes Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Genital Herpes Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Genital Herpes Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Genital Herpes Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Genital Herpes Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Genital Herpes Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Male Table 30. Significant Companies of Female Table 31. Global Genital Herpes Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Genital Herpes Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Genital Herpes Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Genital Herpes Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Genital Herpes Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Genital Herpes Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Genital Herpes Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Genital Herpes Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Genital Herpes Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Genital Herpes Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Genital Herpes Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Genital Herpes Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Genital Herpes Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Genital Herpes Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Genital Herpes Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Genital Herpes Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Genital Herpes Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Genital Herpes Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Genital Herpes Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Genital Herpes Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Genital Herpes Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Genital Herpes Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Genital Herpes Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Genital Herpes Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Genital Herpes Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Genital Herpes Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Genital Herpes Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Genital Herpes Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Genital Herpes Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Genital Herpes Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Genital Herpes Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Genital Herpes Vaccine Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Genital Herpes Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. GSK Genital Herpes Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Changsheng Biotechnology Company Information Table 69. Changsheng Biotechnology Business Overview Table 70. Changsheng Biotechnology Genital Herpes Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Changsheng Biotechnology Genital Herpes Vaccine Product Portfolio Table 72. Changsheng Biotechnology Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Genital Herpes Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Merck Genital Herpes Vaccine Product Portfolio Table 77. Merck Recent Development Table 78. Beike Bio Company Information Table 79. Beike Bio Business Overview Table 80. Beike Bio Genital Herpes Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Beike Bio Genital Herpes Vaccine Product Portfolio Table 82. Beike Bio Recent Development Table 83. BioNTech Company Information Table 84. BioNTech Business Overview Table 85. BioNTech Genital Herpes Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. BioNTech Genital Herpes Vaccine Product Portfolio Table 87. BioNTech Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Genital Herpes Vaccine Distributors List Table 91. Genital Herpes Vaccine Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Genital Herpes Vaccine Product Image Figure 2. Global Genital Herpes Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Genital Herpes Vaccine Sales (2021-2032) & (k units) Figure 5. Global Genital Herpes Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Genital Herpes Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Zoster Vaccine Live Image Figure 10. Recombinant Zoster Vaccine Image Figure 11. Global Genital Herpes Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Genital Herpes Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Genital Herpes Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Genital Herpes Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Genital Herpes Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Genital Herpes Vaccine Sales Value Share by Type (2021-2032) Figure 17. Male Image Figure 18. Female Image Figure 19. Global Genital Herpes Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Genital Herpes Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Genital Herpes Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Genital Herpes Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Genital Herpes Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Genital Herpes Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Genital Herpes Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Genital Herpes Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Genital Herpes Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Genital Herpes Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Genital Herpes Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Genital Herpes Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Genital Herpes Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Genital Herpes Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Genital Herpes Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Genital Herpes Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Genital Herpes Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Genital Herpes Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Genital Herpes Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Zoster Vaccine Live
  • Recombinant Zoster Vaccine
Applications
  • Male
  • Female
Companies covered
  • GSK
  • Changsheng Biotechnology
  • Merck
  • Beike Bio
  • BioNTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Genital Herpes Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Genital Herpes Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Genital Herpes Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Genital Herpes Vaccine Market Dynamics
  1. 2.1 Genital Herpes Vaccine Industry Trends
  2. 2.2 Genital Herpes Vaccine Industry Drivers
  3. 2.3 Genital Herpes Vaccine Industry Opportunities and Challenges
  4. 2.4 Genital Herpes Vaccine Industry Restraints
3 Genital Herpes Vaccine Market by Company
  1. 3.1 Global Genital Herpes Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Genital Herpes Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Genital Herpes Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Genital Herpes Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Genital Herpes Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Genital Herpes Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Genital Herpes Vaccine Company Product Type and Application
  8. 3.8 Global Genital Herpes Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Genital Herpes Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Genital Herpes Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Genital Herpes Vaccine Market by Type
  1. 4.1 Genital Herpes Vaccine Type Introduction
  2. 4.1.1 Zoster Vaccine Live
  3. 4.1.2 Recombinant Zoster Vaccine
  4. 4.2 Global Genital Herpes Vaccine Sales Volume by Type
  5. 4.2.1 Global Genital Herpes Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Genital Herpes Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Genital Herpes Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Genital Herpes Vaccine Sales Value by Type
  9. 4.3.1 Global Genital Herpes Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Genital Herpes Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Genital Herpes Vaccine Sales Value Share by Type (2021-2032)
5 Genital Herpes Vaccine Market by Application
  1. 5.1 Genital Herpes Vaccine Application Introduction
  2. 5.1.1 Male
  3. 5.1.2 Female
  4. 5.2 Global Genital Herpes Vaccine Sales Volume by Application
  5. 5.2.1 Global Genital Herpes Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Genital Herpes Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Genital Herpes Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Genital Herpes Vaccine Sales Value by Application
  9. 5.3.1 Global Genital Herpes Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Genital Herpes Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Genital Herpes Vaccine Sales Value Share by Application (2021-2032)
6 Genital Herpes Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Genital Herpes Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genital Herpes Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Genital Herpes Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Genital Herpes Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Genital Herpes Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Genital Herpes Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Genital Herpes Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Genital Herpes Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Genital Herpes Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Genital Herpes Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Genital Herpes Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Genital Herpes Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Genital Herpes Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Genital Herpes Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Genital Herpes Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Genital Herpes Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Genital Herpes Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Genital Herpes Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Genital Herpes Vaccine Sales Value Share by Country, 2025 VS 2032
7 Genital Herpes Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Genital Herpes Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Genital Herpes Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Genital Herpes Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Genital Herpes Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Genital Herpes Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Genital Herpes Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Genital Herpes Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Genital Herpes Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Genital Herpes Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Genital Herpes Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Genital Herpes Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Genital Herpes Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Genital Herpes Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Changsheng Biotechnology
  8. 8.2.1 Changsheng Biotechnology Company Information
  9. 8.2.2 Changsheng Biotechnology Business Overview
  10. 8.2.3 Changsheng Biotechnology Genital Herpes Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Changsheng Biotechnology Genital Herpes Vaccine Product Portfolio
  12. 8.2.5 Changsheng Biotechnology Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Genital Herpes Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Genital Herpes Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Beike Bio
  20. 8.4.1 Beike Bio Company Information
  21. 8.4.2 Beike Bio Business Overview
  22. 8.4.3 Beike Bio Genital Herpes Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Beike Bio Genital Herpes Vaccine Product Portfolio
  24. 8.4.5 Beike Bio Recent Developments
  25. 8.5 BioNTech
  26. 8.5.1 BioNTech Company Information
  27. 8.5.2 BioNTech Business Overview
  28. 8.5.3 BioNTech Genital Herpes Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BioNTech Genital Herpes Vaccine Product Portfolio
  30. 8.5.5 BioNTech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Genital Herpes Vaccine Value Chain Analysis
  2. 9.1.1 Genital Herpes Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Genital Herpes Vaccine Sales Mode & Process
  6. 9.2 Genital Herpes Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Genital Herpes Vaccine Distributors
  9. 9.2.3 Genital Herpes Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst